Nadia Khan
Austin, TXNPI 1336897644
Payments from drug & device makers
Across 492 payments — averaging $18.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$1K
- AbbVie$1K
- Alkermes, Inc.$885
- Lundbeck LLC$681
- Corium, LLC$593
- Axsome Therapeutics, Inc.$525
- plus $4K from 18 others
What the payments were for
- Food & beverage$8,947100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 64 | $1,252 |
| AbbVie | 49 | $1,081 |
| Alkermes, Inc. | 60 | $885 |
| Lundbeck LLC | 29 | $681 |
| Corium, LLC | 31 | $593 |
| Axsome Therapeutics, Inc. | 28 | $525 |
| Neurocrine Biosciences, Inc. | 17 | $500 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 21 | $380 |
| Tris Pharma Inc | 22 | $372 |
| Teva Pharmaceuticals USA, Inc. | 13 | $349 |
| Neos Therapeutics, LP | 23 | $304 |
| Ironshore Pharmaceuticals Inc. | 18 | $277 |
| Johnson & Johnson | 11 | $277 |
| Idorsia Pharmaceuticals US Inc | 20 | $254 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $236 |
| Supernus Pharmaceuticals, Inc. | 20 | $220 |
| Bausch Health US, LLC | 11 | $211 |
| Vanda Pharmaceuticals Inc. | 13 | $183 |
| Noven Therapeutics, LLC | 8 | $153 |
| Vertical Pharmaceuticals, LLC | 5 | $104 |
| Merck | 3 | $37 |
| Biogen | 1 | $27 |
| OWP Pharmaceuticals, Inc. | 2 | $26 |
| Avion Pharmaceuticals | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$429
- Azstarys$122
- INGREZZA$115
- Austedo XR$102
- VRAYLAR$100
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BelsomraSuvorexant | 13 | $5,605 |
| Fluoxetine Hcl | 12 | $126 |
| Sertraline Hcl | 19 | $41 |
| Alprazolam | 11 | $13 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckBelsomra | $37 | $5,60513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Texason file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.